ReviewTherapeutic advances in hematology2021
Clinical features of
Review in Therapeutic advances in hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation.Annals of hematology · 2026Article
- Inflammatory Signatures in MDS: The Missing Link Between Genetics, Microenvironment, and Therapy.Cells · 2026Review
- Clinical and Molecular Spectrum ofJournal of clinical medicine · 2025Article
- Overall cancer risk in people with deleterious germlineHaematologica · 2025Article
- How to manage patients with germlineHemaSphere · 2024Article
- Article
- Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders.Best practice & research. Clinical haematology · 2024Review
- DDX41: exploring the roles of a versatile helicase.Biochemical Society transactions · 2024Review
- Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease.Frontiers in immunology · 2024Review
- Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.Biomedicines · 2023Article
- Clinical and molecular correlates of somatic and germlineHaematologica · 2023Review
- Favorable outcomes ofEJHaem · 2023Article
- Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.Blood advances · 2023Article
- Article
- How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.Clinical hematology international · 2023Review
- Current Understanding ofCancers · 2023Review
- Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia.Frontiers in oncology · 2023Article
- Consequences of chromosome gain: A new view on trisomy syndromes.American journal of human genetics · 2022Review
- Clinical and mechanistic insights into the roles of DDX41 in haematological malignancies.FEBS letters · 2022Review
- Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms.Current hematologic malignancy reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDDX41 serves as a DNA sensor in innate immunity and mutated
methodsIn this study, "
resultsPooled incidence was 3.3% (95% confidence interval 2.4-4.2%) of unselected myeloid neoplasms. Patients with hematologic disorders harboring mutated
conclusionsSeveral significant clinical differences were observed in different diagnosis groups, familial and sporadic cases, and p.R525H compared with other somatic variants. In conclusion, myeloid neoplasms carrying
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.